UK Earnings, Trading Statements Calendar | |
Thursday, October 22 | |
Inchcape | Q3 Interim Management Statement |
Ladbrokes | Q3 Interim Management Statement |
Lombard Risk Management | Half Year Results |
Stobart | Half Year Results |
Rathbone Brothers | Q3 Interim Management Statement |
Travis Perkins | Q3 Interim Management Statement |
GKN | Q3 Interim Management Statement |
Anglo American | Q3 Production Report |
Britvic | Trading Statement |
Debenhams | Full Year Results |
Foxtons | Trading Statement |
Phoenix Group | Q3 Interim Management Statement |
RELX | Trading Statement |
SEGRO | Trading Statement |
London Stock Exchange Group | Q3 Interim Management Statement |
Polyus Gold International | Trading Statement |
Mothercare | Trading Statement |
Friday, October 23 | |
William Hill | Q3 Interim Management Statement |
Shire | Q3 Results |
Dechra Pharmaceuticals | AGM Trading Statement |
Monday, October 26 | |
WPP | Q3 Trading Statement |
Avacta Group | Full Year Group |
Tuesday, October 27 | |
BP | Q3 Results |
Utilitywise | Full Year Results |
St James's Place | Q3 Interim Management Statement |
Carpetright | Trading Statement |
Shoe Zone | Trading Statement |
Bloomsbury Publishing | Half Year Results |
International Personal Finance | Q3 Interim Management Statement |
Wednesday, October 28 | |
British American Tobacco | Q3 Interim Management Statement |
Standard Life | Q3 Interim Management Statement |
Next | Q3 Trading Statement |
Antofagasta | Q3 Production Report |
GlaxoSmithKline | Q3 Results |
Lloyds Banking Group | Q3 Interim Management Statement |
Redefine International | Full Year Results |
Shanks Group | Trading Statement |
JZ Capital Partners | Half Year Results |
Braemar Shipping | Half Year Results |
Copyright 2015 Alliance News Limited. All Rights Reserved. |
GSK's Jemperli sees success in endometrial cancer trial
(Sharecast News) - GSK reported encouraging outcomes from part one of the 'RUBY' phase three trial evaluating the efficacy of 'Jemperli', or dostarlimab, with standard chemotherapy for treating adult patients with advanced or recurrent endometrial cancer on Monday.
Read more